Fabrice ANDRE
Gustave Roussy, Cancer Campus, Grand Paris · Gustave Roussy, Villejuif · Gustave Roussy, Villejuif, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fabrice ANDRE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07340619 · Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.UNICANCER · not yet recruiting · Metastatic (Stage IV) Melanoma · principal investigator
- Ph2NCT06680596 · Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyUNICANCER · recruiting · Breast Cancer Metastatic, Breast Cancer Stage IV · principal investigator
- Ph2NCT05625087 · Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibUNICANCER · terminated · Breast Cancer Stage IV · principal investigator
- Ph2NCT02997995 · Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureUNICANCER · completed · Breast Cancer, Estrogen Receptor Positive Tumor, Menopause · principal investigator
- Ph2NCT02299999 · SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerUNICANCER · active not recruiting · Metastatic Breast Cancer · principal investigator
- Ph3NCT01805271 · Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone TherapyUNICANCER · active not recruiting · Primary Non-metastatic Breast Cancer, Who Remain Disease-free · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:58 UTC. The ranking covers the 200 most relevant of 149 PubMed records, and a shared surname and initials can bring in a namesake. All 149 on PubMed
- 2,116 citationsRCR 82.3
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.N Engl J Med · 20201,653 citationsRCR 74.7
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.N Engl J Med · 20161,610 citationsRCR 50.2
- DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.N Engl J Med · 20061,398 citationsRCR 31.0
- Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.N Engl J Med · 20151,289 citationsRCR 36.8
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.N Engl J Med · 20181,016 citationsRCR 33.5
- Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.Nat Med · 2014901 citationsRCR 22.3
- 861 citationsRCR 24.9
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.N Engl J Med · 2022703 citationsRCR 49.7
- 643 citationsRCR 32.9